(Q33522784)

27 July 2017

title

Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias (English)

1 reference

27 July 2017

1 reference

3

Emma Loveman

1 reference

27 July 2017

Petra Harris

1

1 reference

27 July 2017

Andrea Takeda

series ordinal

2

1 reference

27 July 2017

Debbie Hartwell

series ordinal

4

1 reference

27 July 2017

publication date

1 January 2010

1 reference

International Journal of Technology Assessment in Health Care

27 July 2017

published in

1 reference

27 July 2017

volume

26

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

110-116

1 reference

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Cancer chemotherapy: identifying novel anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

The price tag on progress--chemotherapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

The effect of scientific misconduct on the results of clinical trials: a Delphi survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Randomized trials stopped early for benefit: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Reporting research results: a moral obligation for all researchers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Factors associated with failure to publish large randomized trials presented at an oncology meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Effect of Addition of Adjuvant Paclitaxel on Radiotherapy Delivery and Locoregional Control of Node-Positive Breast Cancer: Cancer and Leukemia Group B 9344

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

Underreporting research is scientific misconduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

7 January 2021

Full publication of results initially presented in abstracts

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

7 January 2021

Stopping a trial early in oncology: for patients or for industry?

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

7 January 2021

Association between time interval to publication and statistical significance

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990778

7 January 2021

10.1017/S0266462309990778

Identifiers

DOI

1 reference

27 July 2017

1 reference